KurtzkeJF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology1983; 33: 1444–1452.
2.
HobartJFreemanJThompsonA. Kurtzke scales revisited: The application of psychometric methods to clinical intuition. Brain2000; 123: 1027–1040.
3.
KragtJJNielsenJMvan der LindenFA. Disease progression in multiple sclerosis: Combining physicians’ and patients’ perspectives?Mult Scler2011; 17: 234–240.
4.
JohnsonKPBrooksBRCohenJA. Copolymer 1 reduces relapse rate and improves disability in relapsing–remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology1995; 45: 1268–1276.
5.
PhillipsJTGiovannoniGLublinFD. Sustained improvement in expanded disability status scale as a new efficacy measure of neurological change in multiple sclerosis: Treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler2011; 17: 970–979.
6.
EbersGCHeigenhauserLDaumerM. Disability as an outcome in MS clinical trials. Neurology. 2008; 71: 624–631.
7.
TremlettHZhuFPetkauJ. Natural, innate improvements in multiple sclerosis disability. Mult Scler J. 2012; 18: 1412–1421.
8.
Verdier-TailleferMHZuberMLyon-CaenO. Observer disagreement in rating neurologic impairment in multiple sclerosis: Facts and consequences. Eur Neurol1991; 31: 117–119.
9.
GoodkinDECookfairDWendeK. Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the kurtzke expanded disability status scale (EDSS). Multiple Sclerosis Collaborative Research Group. Neurology1992; 42: 859–863.
10.
HolmesTHNicholsDAThomanderD. A method for estimating normative distributions for study-specific populations of clinical trials. Contemp Clin Trials2011; 33(2): 445–449.
11.
SchwidSRGoodmanADApatoffBR. Are quantitative functional measures more sensitive to worsening MS than traditional measures?Neurology2000; 55: 1901–1903.
